Merck & Co., Inc.
One Merck Drive
P.O. Box 100
Whitehouse Station
New Jersey
08889-0100
U.S.A.
Phone:
908-423-1000
Fax:
n/a

|
|
Company Overview
Merck and Co., Inc., Whitehouse Station, NJ USA is a global research-driven pharmaceutical company dedicated to putting patients first. Merck discovers, develops, manufactures, and markets vaccines and medicines in over 20 therapeutic categories directly and through its joint ventures. Our mission is to provide society with superior products and services by developing innovations and solutions that improve the quality of life. The focus of research at Merck is on innovation in all areas of drug research and development, working on programs to satisfy unmet medical needs.
With approximately 60,000 employees, Merck conducts research at ten major research centers in the United States, Europe, and Japan, manufactures products in 30 facilities, and sells products in approximately 150 countries.
At Merck, our strategy for growth is based on breakthrough research - both internal and external through partnerships - and demonstrating the value of our medicines to patients, payers, and providers. Worldwide sales in 2004 were $22.9 billion. Merck continues to invest heavily in research and development, with R&D spending in 2005 estimated to be approximately $4 billion.
Merck's product line includes a broad portfolio of highly innovative prescription products in important therapeutic areas. Human health products include medicines to treat high blood pressure, congestive heart failure, elevated cholesterol levels, osteoporosis, benign prostatic hypertrophy, arthritis, pain, migraine, glaucoma, gastrointestinal ulcers, infectious diseases (antibiotic, anti-fungal, and antiviral agents), and vaccines to prevent childhood diseases and hepatitis A and B.
Embracing Partnerships
At Merck, we are strongly committed to partnership success. We have a long tradition of successful partnerships. Alliances with innovative partners are an integral part of our long-term business and research strategy. More than one-third of our sales are from alliance products and patents, including some of our biggest growth drivers.
Our vision is to create a "virtual lab" - the pursuit of the best scientific programs from both internal research and external collaborations. This approach will accelerate the successful development and commercialization of breakthrough discoveries that can bring meaningful improvements to patients' lives.
Our focus is seeking alliances for new NCE's and biological entities as product candidates for development. We are open to basic research collaborations and early research technologies as well.
Merck welcomes partnerships touching virtually all human health therapeutic areas that address unmet needs for patients, as well as technologies that will enhance the productivity of our research laboratories. Therapeutic areas of particular interest include cancer, central nervous system disorders, diabetes, and obesity. Also of interest include the following: anti-infectives, anti-virals, cardiovascular diseases, gastrointestinal diseases, immunology, new vaccine technology, ophthalmics, osteoporosis, pain, respiratory, vaccines, and platform research technology.
Contact Information
To contact Merck about a licensing opportunity, please contact Chief Licensing Officer, Merck & Co., Inc., One Merck Drive, P.O. Box 100, Whitehouse Station, NJ 08889 USA; Tel: 903-423-4350; Fax: 908-735-1201. Please provide a brief, non-confidential overview of your discovery with sufficient data to allow a preliminary scientific review.
For further information, please visit our website at http://www.merck.com/licensing/
Email:
Ownership:
Web Site:
Merck & Co., Inc.
Employees:
70,000
Symbol: MRK
|
| Collaborations |
|
Actelion Pharmaceuticals US, Inc.
Cardiovascular
|
|
MerLion Pharmaceuticals Pte Ltd
Natural products
|
|
MethylGene
Antibacterials
|
|
Nastech Pharmaceutical Company Inc.
Obesity
|
|
Neurogen Corporation
Pain
|
|
NicOx SA
Nitric oxide-donating compounds
|
|
Norak Biosciences, Inc.
Cell lines
|
|
Ono Pharmaceutical Company, Ltd.
Stroke
|
|
Pierre Fabre
Cancer
|
|
Rigel Pharmaceuticals, Inc.
Cancer
|
|
Roberts Pharmaceutical Corporation
Imaging technology
|
|
SCYNEXIS, Inc.
Antifungals
|
|
Sunesis Pharmaceuticals, Inc.
Alzheimer's disease, Antivirals
|
|
Symyx Technologies, Inc.
High-throughput screening
|
|
Taisho Pharmaceutical
Neuroscience
|
|
TransTech Pharma, Inc.
Diabetes
|
|
University of Edinburgh
Schizophrenia
|
|
WuXi PharmaTech Co., Ltd.
Chemistry
|
|
Kinexis Inc.
Sleep disorders
|
|
Kynin
Infection
|
|
University of Dundee
Kinase consortium
|
|
Arena Pharmaceuticals, Inc.
Cardiovascular
|
|
BioXell S.p.A.
Sepsis
|
|
Cambridge Antibody Technology Group PLC
Antibody technology and library
|
|
Celera Genomics Group-an Applera Corp. Business
Genome databases, Alzheimer's disease, Diagnostics
|
|
Verenium Corporation
Therapeutic antibodies
|
|
Metabasis Therapeutics, Inc.
– Hepatitis C, Diabetes / Hyperlipidemia
|
|
Gilead Sciences, Inc.
|
|
Gilead Sciences, Inc. (Seattle, WA)
|
|
Gilead Sciences, Inc. (Durham, NC)
|
|
Vertex Pharmaceuticals (MA)
(MK-0457 (VX-680), MK-6592 (VX-667) and VX-689 for Cancer)
|
|
Cubist Pharmaceuticals, Inc.
|
|
Acumen Pharmaceuticals Inc.
Alzheimer's disease
|
|
Albany Molecular Research, Inc.
Chemistry
|
|
AMRAD Corporation Limited
Respiratory
|
|
AVEO Pharmaceuticals, Inc.
Cancer
|
|
Bristol-Myers Squibb Company
Diabetes
|
|
Cambridge Major Laboratories, Inc.
Chemistry
|
|
deCODE genetics, Inc.
Obesity, Pharmacogenomics
|
|
DOV Pharmaceutical
Depression
|
|
Exelixis, Inc.
High-throughput screening
|
|
Genetronics, Inc.
DNA vaccine technology
|
|
Intercell AG
Bacterial vaccines
|
|
Kalypsys, Inc.
High-throughput screening
|
|
|
Company News |
GlaxoSmithKline (GSK), Merck & Co., Inc. (MRK) Developing Drugs for Kala Azar, Disease Transmitted by Sandflies
11/20/2009 7:26:17 AM
More...
|
Merck & Co., Inc. (MRK) (JOBS) Receives CHMP Positive Opinion for New Fertility Treatment, ELONVA(R)
11/20/2009 6:28:35 AM
More...
|
Ligand Pharmaceuticals Inc. (LGND) Earns $2 Million in Milestone Payments from Merck & Co., Inc. (MRK)
11/19/2009 8:15:01 AM
More...
|
Higher Dose of Merck & Co., Inc. (MRK)'s COZAAR(R) (losartan potassium tablets) Significantly Reduced Deaths and Hospitalizations Due to Heart Failure In Investigational Study
11/17/2009 8:50:37 AM
More...
|
Merck & Co., Inc. (MRK) Expresses Confidence in the Efficacy and Safety Profiles of ZETIA(R) (ezetimibe) and VYTORIN(R) (ezetimibe/simvastatin) as Effective Medicines for Managing Elevated Cholesterol
11/16/2009 10:30:30 AM
More...
|
Merck & Co., Inc. (MRK) Announces Completion of Patient Enrollment in Phase III TRA-2P-TIMI 50 Trial of SCH 530348, a Novel, Oral Antiplatelet PAR-1 Inhibitor
11/13/2009 9:44:09 AM
More...
|
Merck & Co., Inc. (MRK) CEO Mulls Successor After Merger
11/12/2009 7:40:17 AM
More...
|
Merck & Co., Inc. (MRK) (JOBS) CEO "Actively Looking" for Biotech Deals
11/5/2009 7:50:31 AM
More...
|
Merck & Co., Inc. (MRK) CEO Plans to Keep Schering-Plough Corporation (SGP) Headquarters
11/5/2009 7:38:55 AM
More...
|
New Merck & Co., Inc. (MRK) (JOBS) Begins Operations Worldwide; Now No. 2 Drugmaker, Set for Future Buys
11/4/2009 6:18:05 AM
More...
|
|
|
|